- Home
- Publications
- Publication Search
- Publication Details
Title
Towards precision oncology in advanced prostate cancer
Authors
Keywords
-
Journal
Nature Reviews Urology
Volume 16, Issue 11, Pages 645-654
Publisher
Springer Science and Business Media LLC
Online
2019-10-07
DOI
10.1038/s41585-019-0237-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer
- (2019) Loredana Puca et al. Science Translational Medicine
- Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
- (2019) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC).
- (2019) Michael J. Morris et al. JOURNAL OF CLINICAL ONCOLOGY
- Germline and Somatic Mutations in Prostate Cancer for the Clinician
- (2019) Heather H. Cheng et al. Journal of the National Comprehensive Cancer Network
- Genomic correlates of clinical outcome in advanced prostate cancer
- (2019) Wassim Abida et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The role of lineage plasticity in prostate cancer therapy resistance
- (2019) Himisha Beltran et al. CLINICAL CANCER RESEARCH
- Supraphysiological androgens suppress prostate cancer growth through androgen receptor–mediated DNA damage
- (2019) Payel Chatterjee et al. JOURNAL OF CLINICAL INVESTIGATION
- Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer
- (2018) Yi-Mi Wu et al. CELL
- Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer
- (2018) David A. Quigley et al. CELL
- A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer
- (2018) David Y. Takeda et al. CELL
- Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing
- (2018) Srinivas R. Viswanathan et al. CELL
- Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)
- (2018) Jonathan Welti et al. CLINICAL CANCER RESEARCH
- Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study
- (2018) Rahul Aggarwal et al. JOURNAL OF CLINICAL ONCOLOGY
- Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
- (2018) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study
- (2018) Benjamin A Teply et al. LANCET ONCOLOGY
- The long tail of oncogenic drivers in prostate cancer
- (2018) Joshua Armenia et al. NATURE GENETICS
- Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
- (2018) Maha Hussain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
- (2018) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- LSD1 activates a lethal prostate cancer gene network independently of its demethylase function
- (2018) Archana Sehrawat et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
- (2018) Matti Annala et al. Cancer Discovery
- Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
- (2018) Michael M. Boyiadzis et al. Journal for ImmunoTherapy of Cancer
- Mechanisms of PARP inhibitor sensitivity and resistance
- (2018) Alan D. D’Andrea DNA REPAIR
- Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer
- (2018) Daniel Nava Rodrigues et al. JOURNAL OF CLINICAL INVESTIGATION
- Plasma androgen receptor (pAR) status and activity of taxanes in metastatic castration resistant prostate cancer (mCRPC).
- (2018) Vincenza Conteduca et al. JOURNAL OF CLINICAL ONCOLOGY
- Plasma androgen receptor and serum chromogranin A in advanced prostate cancer
- (2018) Vincenza Conteduca et al. Scientific Reports
- Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency
- (2018) Zafeiris Zafeiriou et al. EUROPEAN UROLOGY
- Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
- (2018) Adam Sharp et al. JOURNAL OF CLINICAL INVESTIGATION
- Aurora-A kinase inhibition is synthetic lethal with loss of the RB1 tumor suppressor gene
- (2018) Xueqian Gong et al. Cancer Discovery
- Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade
- (2018) Wassim Abida et al. JAMA Oncology
- AKT Inhibition in Solid Tumors With AKT1 Mutations
- (2017) David M. Hyman et al. JOURNAL OF CLINICAL ONCOLOGY
- Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer
- (2017) Alexander W Wyatt et al. JNCI-Journal of the National Cancer Institute
- HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer
- (2017) Daniel Hettel et al. Nature Reviews Urology
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
- (2017) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
- (2017) Nicholas D. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- PARP inhibitors: Synthetic lethality in the clinic
- (2017) Christopher J. Lord et al. SCIENCE
- SOX2 promotes lineage plasticity and antiandrogen resistance in TP53 - and RB1 -deficient prostate cancer
- (2017) Ping Mu et al. SCIENCE
- Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance
- (2017) Sheng Yu Ku et al. SCIENCE
- Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories
- (2017) Renea A. Taylor et al. Nature Communications
- BET Proteins as Targets for Anticancer Treatment
- (2017) Anastasios Stathis et al. Cancer Discovery
- Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors
- (2017) David Quigley et al. Cancer Discovery
- Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
- (2017) Jane Goodall et al. Cancer Discovery
- Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer
- (2017) Alexander W Wyatt et al. JNCI-Journal of the National Cancer Institute
- N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer
- (2016) Etienne Dardenne et al. CANCER CELL
- Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer
- (2016) Heather H. Cheng et al. EUROPEAN UROLOGY
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
- (2016) Nicholas D James et al. LANCET
- HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study
- (2016) Jason W D Hearn et al. LANCET ONCOLOGY
- BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer
- (2016) I. A. Asangani et al. MOLECULAR CANCER RESEARCH
- Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer
- (2016) Akash Kumar et al. NATURE MEDICINE
- Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
- (2016) Himisha Beltran et al. NATURE MEDICINE
- Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
- (2016) Colin C. Pritchard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer
- (2016) Alexander W. Wyatt et al. JAMA Oncology
- Integrative Clinical Genomics of Advanced Prostate Cancer
- (2015) Dan Robinson et al. CELL
- The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer
- (2015) H. Beltran et al. CLINICAL CANCER RESEARCH
- Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers
- (2015) A. M. Aparicio et al. CLINICAL CANCER RESEARCH
- Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
- (2015) A. A. Azad et al. CLINICAL CANCER RESEARCH
- Efficacy of Enzalutamide Following Abiraterone Acetate in Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer Patients
- (2015) Arun A. Azad et al. EUROPEAN UROLOGY
- PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
- (2015) Roberta Ferraldeschi et al. EUROPEAN UROLOGY
- The evolutionary history of lethal metastatic prostate cancer
- (2015) Gunes Gundem et al. NATURE
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
- (2015) Christopher J. Sweeney et al. NEW ENGLAND JOURNAL OF MEDICINE
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Plasma AR and abiraterone-resistant prostate cancer
- (2015) Alessandro Romanel et al. Science Translational Medicine
- Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
- (2015) P. A. Konstantinopoulos et al. Cancer Discovery
- Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation
- (2014) Jonathan I. Epstein et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Selectively Targeting the DNA-binding Domain of the Androgen Receptor as a Prospective Therapy for Prostate Cancer
- (2014) Kush Dalal et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Cancer Epigenetics: Tumor Heterogeneity, Plasticity of Stem-like States, and Drug Resistance
- (2014) Hariharan Easwaran et al. MOLECULAR CELL
- Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
- (2014) Irfan A. Asangani et al. NATURE
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor clone dynamics in lethal prostate cancer
- (2014) S. Carreira et al. Science Translational Medicine
- Lysine-Specific Demethylase 1 Has Dual Functions as a Major Regulator of Androgen Receptor Transcriptional Activity
- (2014) Changmeng Cai et al. Cell Reports
- Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
- (2013) Y. Loriot et al. ANNALS OF ONCOLOGY
- Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide
- (2013) K. L. Noonan et al. ANNALS OF ONCOLOGY
- Punctuated Evolution of Prostate Cancer Genomes
- (2013) Sylvan C. Baca et al. CELL
- A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer
- (2013) Kai-Hsiung Chang et al. CELL
- Tracking the clonal origin of lethal prostate cancer
- (2013) Michael C. Haffner et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeting cell cycle and hormone receptor pathways in cancer
- (2013) C E S Comstock et al. ONCOGENE
- DNA Methylation Alterations Exhibit Intraindividual Stability and Interindividual Heterogeneity in Prostate Cancer Metastases
- (2013) M. J. Aryee et al. Science Translational Medicine
- An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
- (2013) M. Korpal et al. Cancer Discovery
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
- (2011) Brett S. Carver et al. CANCER CELL
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets
- (2011) H. Beltran et al. Cancer Discovery
- Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor
- (2010) Raymond J. Andersen et al. CANCER CELL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search